Healthcare
Pharnext: Consolidation Of Shares Making Up Its Share Capital
- March 24, 2023 08:33 AM CET | Reuters

March 24 (Reuters) - Pharnext SA: * CONSOLIDATION OF SHARES MAKING UP ITS SHARE CAPITAL, AT RATE OF 1 NEW SHARE AGAINST 10,000 OLD ONES * OPERATIONS WILL BEGIN ON APRIL 9, 2023 AND COMPLETE ON MAY 9,
Gensight Biologics Cash Runway Confirmed To June 2023
- March 24, 2023 07:41 AM CET
- Reuters
Celyad Oncology Appoints Georges Rawadi As Its New CEO
- March 24, 2023 07:01 AM CET
- Reuters
Celyad Oncology Reports Full Year 2022 Financial Results And Recent Business Highlights
- March 23, 2023 10:36 PM CET
- Reuters
Virbac FY Consolidated Net Income Rises 4.9% At EUR 121.3 Mln
- March 23, 2023 06:06 PM CET
- Reuters

UPDATE 5-Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data
- March 23, 2023 01:24 PM CET | Reuters
* Drug meets primary and all secondary goals in COPD trial * Previous peak sales estimate of 13 bln euros was without COPD * Drug could be first new COPD treatment in over a decade (Adds Regeneron
Read More...
Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data
- March 23, 2023 09:42 AM CET | Reuters
* Drug meets primary and all secondary goals in COPD trial * Previous peak sales estimate of 13 bln euros was without COPD * Drug could be first new COPD treatment in over a decade (Adds share price
Read More...
Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data
- March 23, 2023 09:04 AM CET | Reuters
* Drug meets primary and all secondary goals in COPD trial * Previous peak sales estimate of 13 bln euros was without COPD * Drug could be first new COPD treatment in over a decade (Adds analyst
Read More...
Sanofi, Regeneron's Dupixent shows promise as 'smoker's lung' drug
- March 23, 2023 08:14 AM CET | Reuters
* Drug meets primary and all secondary goals in COPD trial * Previous peak sales estimate of 13 bln eur was without COPD * Drug could be first new COPD treatment in over decade (Adds Dupixent sales,
Read More...
Poxel Announces Cash Runway Extended Through Q2 2025
- March 23, 2023 07:46 AM CET | Reuters
March 23 (Reuters) - Poxel Sa: * POXEL ANNOUNCES CASH RUNWAY EXTENDED THROUGH Q2 2025 BASED UPON DEBT RESTRUCTURING AGREEMENT AND NEW EQUITY-LINKED FINANCING FACILITY * COMPANY EXPECTS THAT ITS
Read More...
Sanofi, Regeneron's Dupixent shows promise as 'smoker's lung' drug
- March 23, 2023 07:45 AM CET | Reuters
(Releads, adds background on Dupixent) By Ludwig Burger and Juby Babu March 23 (Reuters) - Sanofi's asthma and eczema drug Dupixent met all targets in a trial to treat "smoker's lung", giving a major
Read More...
Poxel FY Net Loss EUR 31.4 Mln
- March 23, 2023 07:33 AM CET | Reuters
March 23 (Reuters) - Poxel SA: * POXEL REPORTS FINANCIAL RESULTS FOR FULL YEAR 2022 AND PROVIDES CORPORATE UPDATE * POXEL REPORTED REVENUES OF EUR 0.674 MILLION FOR YEAR ENDED DECEMBER 31, 2022, * NET
Read More...
Sanofi Says Dupixent Shows Reduction In Exacerbations In Phase 3 Trial As A Potential Treatment For COPD
- March 23, 2023 07:11 AM CET | Reuters
March 23 (Reuters) - Sanofi SA: * SANOFI-DUPIXENT SHOWS REDUCTION IN EXACERBATIONS IN PHASE 3 TRIAL AS A POTENTIAL TREATMENT FOR COPD * SANOFI-PHASE 3 TRIAL OF DUPIXENT SHOWED SIGNIFICANT REDUCTION (
Read More...
Innate Pharma End-2022 Cash Position Of EUR 136.6 Million
- March 23, 2023 07:09 AM CET | Reuters
March 23 (Reuters) - Innate Pharma SA: * CASH POSITION OF EUR 136.6 MILLION AS OF DECEMBER 31, 2022 * REVENUE AND OTHER INCOME FROM CONTINUING OPERATIONS AMOUNTED TO EUR 57.7M IN 2022 (2021: EUR 24.7M
Read More...
Valneva Eyes EUR 220-260 Mln In Revenues And Other Income In 2023
- March 23, 2023 07:07 AM CET | Reuters
March 23 (Reuters) - Valneva SE: * VALNEVA REPORTS FULL YEAR 2022 RESULTS AND PROVIDES CORPORATE UPDATES * STRONG CASH POSITION OF EUR 289.4MILLION AT DECEMBER 31, 2022 * TOTAL REVENUES OF EUR 361.3
Read More...